Added to YB: 2025-08-14
Pitch date: 2025-08-12
NOVO-B.CO [neutral]
Novo Nordisk A/S
-23.57%
current return
Author Info
Quality Stocks helps you find valuable insights to become a better investor, discover quality companies, and find investment ideas. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 309.95
Price Target
750.00 (+217%)
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
turnaround
Stock of the Week - Novo Nordisk: A Fall from Grace Hiding Untapped Opportunities?
NOVO-B.CO (overview): New CEO facing increased competition (Eli Lilly) & US price pressure. Q2 strong but FY25 guidance cut to 8-14%. Stock near pre-GLP-1 levels offers good risk/reward despite margin squeeze risk. Still ~10% growth, strong FCF, large market share. Buying zones: 310DKK, 220DKK, 160DKK.
Read full article (2 min)